Invirsa's lead compound, INV-102, is derived from a naturally occurring molecule that combats viral conjunctivitis (viral pinkeye) by enhancing the body's own ability to fight the disease.
Location: United States, Ohio, Columbus
Employees: 1-10
Total raised: $8.22M
Investors 2
| Date | Name | Website |
| - | Rev1 Ventu... | rev1ventur... |
| - | Ohio Innov... | ohioinnova... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.06.2023 | Series B | $7.7M | Rev1 Ventu... |
| 07.11.2017 | Seed | $520K | - |
Mentions in press and media 6
| Date | Title | Description | Source |
| 15.06.2023 | Invirsa Closes $7.7M Series B Financing | Invirsa, a Columbus, OH-based clinical-stage pharmaceutical company, raised $7.7M in Series B fundin... | finsmes.co... |
| 15.06.2023 | CincyTech leads $7.7M round for Columbus-based pharma startu... | - | bizjournal... |
| 14.06.2023 | Invirsa Completes $7.7M Series B Financing | COLUMBUS, OH, Invirsa, a privately held, clinical-stage pharmaceutical company, announced the clos... | vcnewsdail... |
| 07.11.2017 | Invirsa Secures $520K in Seed Funding | Invirsa, a Columbus, Ohio-based pharmaceutical company developing a new line of attack against commo... | finsmes.co... |
| - | Invirsa | - | fastfounde... |
| - | Invirsa: Clinical-Stage Pharmaceutical Company Secures $7.7 ... | Invirsa – a privately held, clinical-stage pharmaceutical company focused on developing an innovativ... | pulse2.com... |